Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19249149 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL13602684 | 0.97 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| SCHEMBL15706255 | 0.90 | — | — | |
| SCHEMBL12619778 | 0.84 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL23683081 | 0.79 | — | — | |
| SCHEMBL17523775 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHR | |
| SCHEMBL17523760 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHR | |
| SCHEMBL20646820 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHR | |
| SCHEMBL23873076 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHR | |
| SCHEMBL12830232 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-20170119033-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | SENOMYX INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | ALDH1A1 2370/4885TSHR 3858/4885 |
| US-20170119033-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | TREH, SNRPE, CEL | ALDH1A1 3968/4885TSHR 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.